These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 3817597)
41. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women. Buckler H; Al-Azzawi F; BJOG; 2003 Aug; 110(8):753-9. PubMed ID: 12892687 [TBL] [Abstract][Full Text] [Related]
42. [Urogenital complaints: value of systemic estrogen therapy]. Hänggi W; Dörflinger A Praxis (Bern 1994); 1997 Aug; 86(33):1260-3. PubMed ID: 9381012 [TBL] [Abstract][Full Text] [Related]
43. Benefit and safety of 28-day transdermal estrogen regimen during vaginal hysterectomy (a controlled trial). Vesna A; Neli B Maturitas; 2006 Feb; 53(3):282-98. PubMed ID: 16011883 [TBL] [Abstract][Full Text] [Related]
44. [Gestagens and hormone substitution]. Klinger G Zentralbl Gynakol; 1995; 117 Suppl():25-9. PubMed ID: 8571690 [No Abstract] [Full Text] [Related]
47. [Patches: a new way for substitute estrogen therapy]. Palacios S Med Clin (Barc); 1990 Sep; 95(9):336-7. PubMed ID: 2280618 [No Abstract] [Full Text] [Related]
48. [The treatment of the climacteric syndrome]. Barinov AM Med Sestra; 1991 Jun; 50(6):27-9. PubMed ID: 1943614 [No Abstract] [Full Text] [Related]
49. Estrogen replacement therapy. Effect on blood pressure and other cardiovascular risk factors. Kaplan NM J Reprod Med; 1985 Oct; 30(10 Suppl):802-4. PubMed ID: 4078812 [TBL] [Abstract][Full Text] [Related]
50. [The current state of knowledge of the side effects of high-dose estrogen therapy]. Klinger G; Carol W; Jahreis G Padiatr Grenzgeb; 1990; 29(2):167-74. PubMed ID: 2352747 [No Abstract] [Full Text] [Related]
51. Dose dependent response of symptoms, pituitary, and bone to transdermal oestrogen in postmenopausal women. Stevenson JC; Shennan NM; Whitehead MI Br Med J (Clin Res Ed); 1987 Jan; 294(6565):181. PubMed ID: 3109564 [No Abstract] [Full Text] [Related]
52. [Principles of hormonal therapy in menopause]. Maleeva A Akush Ginekol (Sofiia); 1989; 28(4):78-84. PubMed ID: 2679195 [No Abstract] [Full Text] [Related]
53. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status. Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR Menopause; 2008; 15(1):94-7. PubMed ID: 17882008 [TBL] [Abstract][Full Text] [Related]
54. Estrogen use and cardiovascular disease. Henderson BE; Ross RK; Paganini-Hill A J Reprod Med; 1985 Oct; 30(10 Suppl):814-20. PubMed ID: 4078814 [TBL] [Abstract][Full Text] [Related]
55. Vaginal ring delivering estradiol and progesterone: a possible alternative to relieve climacteric symptoms. Ben-Chetrit A; Hochner-Celnikier D; Lindenberg T; Zacut D; Shimonovitz S; Gelber H; Spitz IM Isr Med Assoc J; 2005 May; 7(5):302-6. PubMed ID: 15909462 [TBL] [Abstract][Full Text] [Related]
56. [Continuous, low dosage estradiol administration with a vaginal ring: a placebo-controlled study]. Casper F; Petri E; Benninghoff B Zentralbl Gynakol; 1998; 120(9):449-53. PubMed ID: 9796090 [TBL] [Abstract][Full Text] [Related]
57. Effect of progestins on IGF-I serum level in estrogen-treated postmenopausal women. Campagnoli C; Biglia N; Cantamessa C; Di Sario MM; Lesca L Zentralbl Gynakol; 1997; 119 Suppl 2():7-11. PubMed ID: 9361392 [TBL] [Abstract][Full Text] [Related]
59. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years. Diem S; Grady D; Quan J; Vittinghoff E; Wallace R; Hanes V; Ensrud K Menopause; 2006; 13(1):130-8. PubMed ID: 16607109 [TBL] [Abstract][Full Text] [Related]